top
Search terms
Results 31 - 40 of 116 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 12
Ehjcvp

Abstract Aims Clinical utilization of dual antiplatelet therapy (DAPT) in patients with renal impairment (RI) following percutaneous coronary interventions (PCI) represents an urgent, unmet need ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Long Zhe Guo, Moo Hyun Kim, Chang Heon Shim, Sun Young Choi, Victor L. Serebruany

Date : 01/07/2016
Ehjcvp

Various studies have now raised hope for an additional protective effect of pharmacological DPP4 inhibition in vascular diseases. Besides GLP1, especially, the inhibition of SDF1 cleavage has been ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Friederike Remm, Wolfgang-Michael Franz, Christoph Brenner

Date : 01/07/2016
Ehjcvp

Dear Editor, as explained in the review article on SGLT2 inhibition by de Leeuw et al.,1 SGLT2 is a low-affinity high-capacity cotransporter, expressed proximally in the tubular system (see ...

European Heart Journal - Cardiovascular Pharmacotherapy, CORRESPONDENCE, Francisco Javier Martinez-Martin, Natalia Jimenez-Martin, Nery Sablon-Gonzalez

Date : 30/05/2016 Item size : 108816 bytes
Ehjcvp

Dear Editor, We thank Dr Martinez-Martin et al. for their interest in our article.1 In their letter, the authors question if SGLT1 has no compensatory role during the inhibition of SGLT2 We referred ...

European Heart Journal - Cardiovascular Pharmacotherapy, CORRESPONDENCE, Anne E. de Leeuw, Rudolf A. de Boer

Date : 30/05/2016 Item size : 103449 bytes
Ehjcvp

Introduction Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a P2Y12 inhibitor, is recommended by guidelines for up to 12 months in patients with acute coronary ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Gianluigi Savarese, Stefano Savonitto, Lars H. Lund, Stefania Paolillo, Caterina Marciano, Santo Dellegrottaglie, Antonio ...

Date : 21/04/2016
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes
Ehjcvp

The Systolic Blood Pressure Intervention Trial (SPRINT) enrolled 9300 participants age 50 years and older without diabetes or previous stroke in 100 expert medical centres and clinical practices ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Sverre E. Kjeldsen, Giuseppe Mancia

Date : 01/04/2016 Item size : 128053 bytes
Ehjcvp

In this issue of European Heart Journal: Cardiovascular Pharmacology, Johnson et al. report an observational study on the relationship between conventional risk factors and the incidence of AF in ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Farhan Shahid, Eduard Shantsila, Gregory Y. H. Lip

Date : 01/04/2016 Item size : 149125 bytes
Ehjcvp

Abstract Aims An important decision in the management of patients with atrial fibrillation is whether to adopt a rate or rhythm control strategy. Methods and results We conducted a retrospective ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Carl Hayward, Hitesh C. Patel, Ketna Patel, Carlo Di Mario, Alexander R. Lyon, Syed Y. Ahsan, Edward Rowland

Date : 01/04/2016 Item size : 222623 bytes
Ehjcvp

Introduction Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) have been used in clinical practice for more than a century and are among the most widely used drugs worldwide for the ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Morten Schmidt, Morten Lamberts, Anne-Marie Schjerning Olsen, Emil Fosbøll, Alexander Niessner, Juan Tamargo, Giuseppe Rosano, ...

Date : 01/04/2016 Item size : 461588 bytes